Stay updated on Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:03:23.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:20:19.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page has undergone significant content removal, particularly regarding a clinical trial for Pembrolizumab in non-small cell lung cancer patients, including detailed inclusion and exclusion criteria. A new revision number has been added, indicating an update to the page.
    Difference
    36%
    Check dated 2025-04-16T10:00:36.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T04:56:08.000Z thumbnail image
  7. Check
    96 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T19:04:45.000Z thumbnail image
  8. Check
    111 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T09:24:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.